Sugi Predict

Sugi Predict / Compounds / SCHEMBL2763395

SCHEMBL2763395

SCHEMBL2763395

O=S1(=O)[N]CCc2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ NOS3 P29474 2/20 0.34
▸ NOS2 P35228 2/20 0.34
▸ CA12 O43570 4/20 0.33
▸ CA1 P00915 4/20 0.33
▸ CA2 P00918 4/20 0.33
▸ CA9 Q16790 4/20 0.33
▸ GPR3 P46089 1/20 0.33
▸ TSHR P16473 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ MAOA P21397 2/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ CA4 P22748 2/20 0.31
▸ CA7 P43166 2/20 0.31
▸ NOS1 P29475 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ BCHE P06276 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2782984 0.78 CA12 (0.39) RAB9AL3MBTL1CA12CA1CA2
SCHEMBL7346113 0.73 CA12 (0.40) RAB9ASIGMAR1L3MBTL1NOS3NOS2
SCHEMBL19820978 0.70 GPR3 (0.52) RAB9ASIGMAR1NOS3NOS2CA12
SCHEMBL349152 0.68 CA12 (0.42) RAB9AL3MBTL1CA12CA1CA2
SCHEMBL30533792 0.67 CA1 (0.47) RAB9ASIGMAR1CA12CA1CA2
SCHEMBL61667 0.67 CA1 (0.47) RAB9ASIGMAR1CA12CA1CA2
SCHEMBL11750709 0.67 CES1 (0.39) RAB9ASIGMAR1NOS3NOS2CA12
SCHEMBL465345 0.67 CA12 (0.37) RAB9AL3MBTL1CA12CA1CA2
Hydrochloric Acid SCHEMBL11752423 0.65 CES1 (0.38) RAB9ASIGMAR1NOS3NOS2CA12
SCHEMBL7346490 0.64 PKM (0.40) RAB9AL3MBTL1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2174939-A1 Pyranones useful as ATM inhibitors Kudos Pharmaceuticals Limited (GB) 2010-04-14 — — EP disclosed
US-7696203-B2 DNA-PK inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2010-04-13 — — US disclosed
EP-1654257-B1 AMINOPYRONES AND THEIR USE AS ATM INHIBITORS KUDOS PHARM LTD (GB) 2010-03-17 — — EP disclosed
US-7674823-B2 DNA-PK inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2010-03-09 — — US disclosed
EP-2046768-A1 SYNTHESIS OF 2-AMINO-SUBSTITUTED 4-OXO-4H-CHROMEN-8.YL-TRIFLUORO-METHANESULFONIC ACID ESTERS Kudos Pharmaceuticals Limited (GB) 2009-04-15 — — EP disclosed
US-20090035394-A1 USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES KUDOS PHARMACEUTICALS LIMITED (GB) 2009-02-05 — — US disclosed
EP-1417196-B1 DNA-PK INHIBITORS CANCER REC TECH LTD (GB) 2008-10-22 — — EP disclosed
US-7429660-B2 ATM inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2008-09-30 — — US disclosed
WO-2008009934-A1 SYNTHESIS OF 2-AMINO-SUBSTITUTED 4-OXO-4H-CHROMEN-8.YL-TRIFLUORO-METHANESULFONIC ACID ESTERS KUDOS PHARMACEUTICALS LIMITED (GB) 2008-01-24 — — WO disclosed
US-20070238729-A1 DNA-PK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-10-11 — — US disclosed
US-7226918-B2 DNA-PK inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2007-06-05 — — US disclosed
US-20060264427-A1 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents KUDOS PHARMACEUTICALS LIMITED (GB) 2006-11-23 — — US disclosed
US-7105518-B2 Thiopyrane-4-ones as DNA protein kinase inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-09-12 — — US disclosed
US-7049313-B2 ATM inhibitors KUDOS PHARMACEUTICALS LTD. (GB) 2006-05-23 — — US disclosed
WO-2006032869-A1 DNA-PK INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2006-03-30 — — WO disclosed
EP-1416936-B1 THIOPYRANE-4-ONES AS DNA PROTEIN KINASE INHIBITORS CANCER REC TECH LTD (GB) 2005-06-01 — — EP disclosed
US-20050107367-A1 Thiopyrane-4-ones as dna protein kinase inhibitors CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2005-05-19 — — US disclosed
US-20050054657-A1 ATM inhibitors KUDOS PHARMACEUTICALS LIMITED (GB) 2005-03-10 — — US disclosed
US-20040192687-A1 Dna-pk inhibitors CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 2004-09-30 — — US disclosed
US-20040002492-A1 Induce immunology response; anticancer agents KUDOS PHARMACEUTICALS LTD (GB) 2004-01-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002492-A1 Induce immunology response; anticancer agents MYD88, IFNG, HCCS RAB9A 2806/4885SIGMAR1 3877/4885L3MBTL1 2434/4885
US-20040192687-A1 Dna-pk inhibitors ATM, CHEK1, XRCC6 RAB9A 4313/4885SIGMAR1 3377/4885L3MBTL1 2433/4885
US-20070238729-A1 DNA-PK INHIBITORS ATM, CHEK2, CHEK1 RAB9A 4426/4885SIGMAR1 3679/4885L3MBTL1 2342/4885
US-20090035394-A1 USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES ATM, CHEK2, DCK RAB9A 3423/4885SIGMAR1 4804/4885L3MBTL1 891/4885
US-20050107367-A1 Thiopyrane-4-ones as dna protein kinase inhibitors DTYMK, DCK, TK1 RAB9A 4031/4885SIGMAR1 2405/4885L3MBTL1 825/4885
US-20050054657-A1 ATM inhibitors ATM, ATR, CHEK2 RAB9A 3006/4885SIGMAR1 4382/4885L3MBTL1 881/4885
US-20060264427-A1 3-amino-N-[4-(2-morpholin-4-yl-1-benzopyran-4-one)-dibenzofuran-1-yl]-propionamides ; anticancer, antitumor agents POLK, DCK, POLN RAB9A 4690/4885SIGMAR1 2654/4885L3MBTL1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.